EP1848506A2 - Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole - Google Patents

Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole

Info

Publication number
EP1848506A2
EP1848506A2 EP06748243A EP06748243A EP1848506A2 EP 1848506 A2 EP1848506 A2 EP 1848506A2 EP 06748243 A EP06748243 A EP 06748243A EP 06748243 A EP06748243 A EP 06748243A EP 1848506 A2 EP1848506 A2 EP 1848506A2
Authority
EP
European Patent Office
Prior art keywords
chloro
phenyl
benzodiazepine
pyrimido
tetraaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06748243A
Other languages
German (de)
English (en)
Inventor
Xu Bai Bai
Qun Dang
Robert J. Ternansky Ternansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Discovery Sciences Ltd
Tactic Pharma LLC
Original Assignee
Changchun Discovery Sciences Ltd
Attenuon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Discovery Sciences Ltd, Attenuon LLC filed Critical Changchun Discovery Sciences Ltd
Publication of EP1848506A2 publication Critical patent/EP1848506A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to pyrimidine-fused benzodiazepine derivative and indole-fused pteridine compounds.
  • the invention further relates to libraries containing two or more of such compounds and methods of making such compounds.
  • the invention also relates to methods of screening for bioactive pyrimidine-fused benzodiazepine derivative and indole-fused pteridine compounds for the treatment or prevention of diseases such as cancer.
  • Heterocyclic compounds are often considered privileged structures in medicinal chemistry due to their various biological effects, and there are numerous reports of heterocyclic scaffolds containing the benzodiazepine moiety which show significant biological activities (Evans et al, J. Med. Chem. 1988, 31, 2235-2246; Evans et al., Bioorg. Med. Chem. Lett. 2001, 11, 1297-1300; Wyatt et al., Bioorg. Med. Chem. Lett. 2001, 11, 1301-1305; Stevens et al., J. Am. Chem. Soc. 1996, 118, 10650-10651). [0003] Benzodiazepine derivatives are probably the most explored compound class in drug discovery.
  • Clozapine, Olanzapine and Quetiapine are used to treat schizophrenia (Campiani et al., J. Med. Chem. 2002, 45, 344; Campiani et al., J. Med. Chem. 2004, 47, 143; Mouithys-Mickalad et al., J. Med. Chem. 2001, 44, 769); Clonazepam, Diazepam, Lorazepam, Nitrazepam and Oxazepam are used as antianxiety drugs; Midazolam is a phenobarbital-like compound typically used for anesthesia.
  • CCK cholecystokinin receptor
  • Tricyclic diazepine derivatives are known anti-inflammatory, anti-anginal, anti-secretory (gastric acid), anti-muscarinic, anti-arrhythmic, anti-depressant, analgesic, antipsychotic, anxiolytic, anti-convulsant, anti-neoplastic, anti-mitotic, anti-hypertensive, antiallergic, anti-asthmatic, antibiotic, anti-diabetic, anti-histamine, cardiotonic, and spasmolytic agents.
  • GABA A/benzodiazepine receptor complex related drugs microtubule inhibitors, endothelin antagonists, muscarinic (M2) antagonists, vasopressin Vl antagonists, vasopressin V2 antagonists and lipoxygenase inhibitors.
  • pyrimidines Another widely studied class of compounds are pyrimidines and pyrimidine- fused compounds because of their interesting pharmacological activities and structural similarity to the naturally-occuring nucleosides.
  • some pyrrolopyrimidines are reported to have anti-tumor activities (Wang et al., J. Med. Chem. 2004, 47, 1329)
  • some aminopyridopyrimidines are non-nucleoside adenosine kinase inhibitors (Perner et al., J. Med. Chem. 2003, 46, 5249)
  • certain furanopyrimidines are potent and selective inhibitors of human cytomegalovirus (HCMV) (McGuigan et al., J. Med. Chem. 2004, 47, 1847)
  • 5- substituted furo[2,3-d]pyrimidines exhibit potent inhibitory activity against the growth of tumor cells (Gangjee et al., J. Med. Chem. 2004, 47,
  • a related class of compounds to the benzodiazepines are pyrimidine-fused pteridines, which have been reported to exhibit a variety of biological activities and constitute the backbones of several marketed drugs.
  • the antifolate drug methotrexate is used as an antitumor agent and triamterene as diuretics.
  • Other pteridines are reported to have activities against biological targets such as alkyltransferase, adenosine kinase, mycobacterial FtsZ, xanthine oxidase and neuronal nitric oxide synthase (Nelson et al., J. Med. Chem. 2004, 47, 3887; Gomtsyan et al., Bioorg. Med. Chem. Lett. 2004, 14, 4165; Reynolds et al., Bioorg. Med. Chem. Lett.
  • the present invention relates to pyrimidine-fused benzodiazepines and pyrimidine-fused pteridines, and libraries of such compounds. These compounds based on privileged structures are important for use in libraries against broad drug screening targets for new leads and may be used as the basic structures for drug discovery.
  • a compound of the invention is purified.
  • the invention provides a compound of formula:
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom;
  • R, R 1 , R 2 alkyl, aryl or a heterocycle.
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom;
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 alkyl, aryl or a heterocycle.
  • Nu halogen
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom;
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 alkyl, aryl or a heterocycle.
  • Nu halogen
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • X O, S, or NR;
  • Nu R 4 S, R 4 O or NR 5 R 6 ;
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom; and
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 alkyl, aryl or a heterocycle.
  • Nu halogen.
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • X O, S, or NR;
  • Nu R 4 S, R 4 O or NR 5 R 6 ;
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom;
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 alkyl, aryl or a heterocycle.
  • Nu halogen.
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • R 7 H, CH 3 , or F
  • R 8 4'-F-C 6 H 4 , 4'-CH 3 -C 6 H 4 , or 4'-NO 2 -C 6 H 4 .
  • the invention provides a compound of formula:
  • NHR 9 R 10 is n-Bu-NH 2 or pyrrolidine.
  • the compound is 4-chloro-l l-methyl-6- propylpyrimido ⁇ -blCl ⁇ Jbenzodiazepine ⁇ -chloro- ⁇ l-dimethylpyrimido ⁇ - b] [ 1 ,4]benzodiazepine; 4-chloro- 11 -methyl-6-phenyrpyrimido[4,5 ⁇ &] [ 1 ,4]benzodiazepine; 4- chloro-1 l-methyl-6-(4'-fluorophenyl)-pyrimido[4,5-Z?][l,4]benzodiazepine; 4-chloro-l 1- methyl-6-(4'-methyl-phenyl)-pyrimido[4,5-b][l,4]benzodiazepine; 4-chloro-l l-methyl-6-(4'- nitro-phenyl)-pyrimido[4,5-b][l,4]benzodiazepine; 4-chloro-8,ll-dimethyl-6-
  • the invention also provides methods for making tricyclic 4-chloro- pyrimido[4,5-&][l,4]benzodiazepines and derivatives.
  • the method comprises reacting a 6-chloro-4,5-diaminopyrimidine with an acid or acid derivative to form a 4-chloro-pyrimido[4,5-b][l,4]benzodiazepine.
  • the method further comprises conducting a nucleophilic substitution reaction on said 4-chloro-pyrimido[4,5- £>][l,4]benzodiazepine.
  • the method further comprises hydrogenating the 4-substituted-pyrimido[4,5-&][l,4]benzodiazepine under hydrogenation reaction conditions or reacting the 4-substituted-pyrimido[4,5-Z>][l,4]benzodiazepine with organometallic reagent.
  • the method further comprises amide formation, alkylation, or sulfonamide formation.
  • Rl H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle or halogen;
  • R2 alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle.
  • the compound is 4-Chloro- 1 l-methyl-6-propyl-
  • the invention also provides methods for making tricyclic pyrimidine-fused
  • the method comprises reacting a 6-chloro- 4,5-diaminopyrimidine with an aldehyde to form a 4-chloro-dihydropyrimido[4,5- b][l ⁇ benzodiazepine.
  • the method further comprises a nucleophilic substitution of the 4-chloro group.
  • the invention provides a compound of formula:
  • R 2 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle, halogen or alkoxy;
  • R 3 alkyl, substituted alkyl, aryl, heterocycle, substituted heterocycle, heteroaryl, or substituted aryl.
  • R 2 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle, or halogen.
  • R 2 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle or halogen;
  • R 4 , R 5 H, alkyl, substituted alkyl, aryl, substitute aryl, heterocycle, substituted heterocycle, or R 4 and R 5 together form a cyclic alkyl.
  • the compound is 4-(Phenylthio)-6- phenylpyrimido[4,5-b] [1 ,4]benzothiazepine; 4-(Phenylthio)-6-(pyridin-3-yl)-pyrimido[4,5- b] [ 1 ,4]benzothiazepine; 4-(Phenylthio)-6-p-tolylpyrimido[4,5- ⁇ ] [ 1 ,4]benzothiazepine; 4- (Phenylthio)-6-(o-nitrophenyl)pyrimido[4,5-b] [ 1 ,4]benzothiazepine; 4-(Phenylthio)-6-(o- nitrophenyl)pyrimido[4,5-b] [ 1 ,
  • the invention also provides methods for making tricyclic pyrimido[4,5- b][l,4]benzothiazepines.
  • the method comprises reacting a 5 ⁇ amino-4,6-
  • the method further comprises oxidation of the phenylthio group of the pyrimido[4,5-&][l,4]benzothiadiazepine to the corresponding sulfoxide or sulfone. In other embodiments, the method further comprises nucleophilic substitution with an amine.
  • the invention provides a compound of:
  • X Cl, R 3 R 4 N, R 3 O, R 3 S, or aryl
  • R 1 , R 2 H, alkyl, substituted alkyl, aryl, substituted aryl or R 1 and R 2 together form a cyclic alkyl;
  • R 3 , R 4 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle.
  • the compound is 8-chloro-6-ethyl- 1,2,6,7- tetrahydro-7,9,11,1 lb-tetraaza-dibenzo[c,d,h]azulene; 8-chloro-6-propyl-l,2,6,7-tetrahydro- 7,9,11,1 lb-tetraaza-dibenzo[c,d,h]azulene; 8-chloro-6-phenyl-l,2,6,7-tetrahydro-7,9,l 1,1 Ib- tetraaza-dibenzo[c,d,h]azulene; 8-chloro-6-(o-methoxyphenyl)-l,2,6,7-tetrahydro-7,9,l 1,1 Ib- tetraaza-dibenzo[c,d
  • the invention also provides methods for making tetracyclic pyrimidine-fused benzodiazepines.
  • the method comprises reacting an indolin-1- ylpyrimidine or tetrahydroquinolin-1-ylpyrimidine with aliphatic or aromatic aldehydes or ketones to form a a tetracyclic pyrimidobenzodiazepine.
  • the method further comprises a nucleophilic substitution.
  • the invention provides a compound of formula:
  • R alkyl, substituted alkyl, aryl, substituted aryl.
  • the compound is 4-chloro-6-ethyl-5,6- dihydroindolo[2,l-h] ⁇ teridine; 6-butyl-4-chloro-5,6-dihydroindolo[2,l-h]pteridine; 4-chloro- 6- ⁇ henyl-5,6-dihydroindolo[2,l-h]pteridine; 4-chloro-6-(4'-rnethylphenyl)-5,6 ⁇ dihydroindolo[2,l-h]pteridine; 4-chloro-6-(4'-nitrophenyl)-5,6-dihydroindolo[2,l-h]pteridine; 4-chloro-6-(3',4'-dichlorophenyl)-5,6-dihydroindolo[2,l-h]pteridine; 4-chloro-6-(o- methoxyphenyl)-5,6-di
  • the invention also provides methods for making indole-fused pyrimidines.
  • the method comprises reacting a 5-amino-4-chloro-6-(l-indolyl)pyrimidine with an aldehyde or ketone to form a 5,6-dihydroindolo[2,l-h]pteridine.
  • the method further comprises a nucleophilic substitution reaction.
  • the invention also provides libraries comprising a plurality of different compounds of the invention. In a specific embodiment, a plurality is two or more, three or more, four or more, five or more, 10 or more, 15 or more, 20 or more or 50 or more compounds of the invention. In specific embodiments, each compound in the library is purified.
  • the invention provides a library wherein each compound in a library is of formula I. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula II. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula III. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula IV. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula V. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula VI. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula VII.
  • the invention provides a library wherein each compound in a library is of formula VIII. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula IX. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula X. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula XI. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula XII. In a specific embodiment, the invention provides a library wherein each compound in a library is of formula XIH. In the foregoing embodiments, the library can be any library of the invention.
  • Methods of screening the libraries of the invention are also provided. Any of the libraries can screened for pharmaceutically desirable activity.
  • the library to be screened contains only compounds from a specific class of compounds, e.g., compounds prepared using the same reactions.
  • the methods of screening libraries of the invention can be applied to an entire library of compounds, a subset of a library, or a single compound in a library.
  • the invention provides a method of screening a library for a candidate compound with a therapeutic activity, comprising:
  • the method further comprises repeating the assay with subsets of the compounds initially tested to identify the compound with modulatory activity.
  • the libraries are tested in kinase assays.
  • kinase activity in the presence of a library is compared to kinase activity in the absence of the library.
  • the invention provides methods for screening a library for a candidate kinase inhibitor, comprising:
  • the kinase is FLT3, KIT, PDGFR-B, RET, SRC, FLTl(VEGFRl), FLT4(VEGFR3), KDR(VEGFR2) or RAF-I
  • the compounds are tested for cytotoxicity with cancer cells, e.g, by a method comprising contacting one or more compounds of the invention with a cancer cell, and determining if increased cancer cell death occurs relative to that in the absence of said compounds.
  • FIG. 1 shows general reaction scheme I for the synthesis of pyrimidine-fused diazepine derivative compounds.
  • FIG. 2 shows reaction scheme II for the synthesis of pyrimidine-fused 5,6- dihydrobenzodiazepines via a Pictet-Spengler-like cyclization.
  • FIG. 3 shows the reaction scheme III for the synthesis of pyrimido[4,5- b][l ,4]benzothiazepines.
  • FIG. 4 shows reaction scheme IV for the synthesis of tetracyclic pyrirnidobenzodiazepines .
  • FIG. 5 shows reaction scheme V for the synthesis of indole-fused pteridines.
  • the present invention relates to pyrimidine-fused benzodiazepines and pyrimidine-fused pteridines, and libraries of a plurality of such compounds.
  • the invention provides methods of making pyrimidine-fused benzodiazepines derivative and pyrimidine- fused pteridine compounds.
  • the various classes of compounds encompassed by the invention are described in detail below.
  • the invention provides a compound of formula:
  • the invention provides a compound of formula:
  • Nu R 4 S, R 4 O or NR 5 R 6 ;
  • Y 1 , Y 2 , Y 3 , and Y 4 H, alkyl, aryl or a heteroatom;
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 alkyl, aryl or a heterocycle.
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • R, R 1 , R 2 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • Y 1 , Y 2 , Y 3 , and Y 4 substituted alkyl, substituted aryl, heterocycle or substituted heterocycle.
  • R, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 substituted alkyl, substituted aryl or substituted heterocycle.
  • the invention provides a compound of formula:
  • R 7 H, CH 3 , or F
  • R 8 4'-F-C 6 H 4 , 4'-CH 3 -C 6 H 4 , or 4'-NO 2 -C 6 H 4 .
  • the invention provides a compound of formula:
  • NHR 9 R 10 is n-Bu-NH 2 or pyrrolidine.
  • the compound is:
  • nucleophilic substitution allows the introduction of one more diversity point in the target molecules.
  • the 4-chloro group can be easily converted to other groups by either a substitution reaction with a nucleophile (such as an amine, alcohol and phenol) or by Suzuki-Miyaura cross-coupling reactions with boronic acids (Chorvat et al., J. Med. Chem. 1999, 42, 833; Gundersen et al., J. Med. Chem. 2002, 45, 1383; Oh et al., Arch. Pharm. Pharm. Med. Chem. 2001, 334, 345; Havelkova et al., Synlett 1999, 1145).
  • the reaction from compound 2 to compound 3 involves a nucleophilic subsitution.
  • reaction conditions employed for reaction step b) may generally include those used in nucleophilic substitution reactions, such as the substitution of a chloro group with an amine group, using a base as a catalyst.
  • Compound 3 can be coverted to either compound 4 or compound 5 using hydrogenation conditions or organometallic reagents.
  • Hydrogenation conditions include H 2 /
  • Organometallic reagents include R 3 MgCl or LiR 3 , wherein R 3 is an alkyl, aryl, or heterocycle.
  • the invention provides a compound of formula:
  • R 2 alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle.
  • the compound is:
  • Tricyclic pyrimidine-fused 5,6-dihydrobenzodiazepines are prepared via a
  • the invention provides a compound of formula:
  • R 2 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle, halogen, heteroatom or alkoxy;
  • R 3 alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted hetercycle.
  • the invention provides a compound of formula:
  • R 2 H, halogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle.
  • the invention provides a compound of formula:
  • R 2 H, halogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle;
  • R 4 , R 5 H, alkyl substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle, or R 4 and R 5 together form a cyclic alkyl.
  • the compound is:
  • Tricyclic pyrimido[4,5-b][l,4]benzothiazepines were prepared by the procedure shown in Scheme III. See Fu et al., 2005, J. Org. Chem., 70, 10810-10816, incorporated by reference herein in its entirety. In general, these compound are prepared from 5-amino-4,6-bis-(arylthio)pyrimidines and carboxylic acids via Bischler-Napieralski- type reactions.
  • Precursor compounds 6 in Scheme 3 were prepared by treating commercially available 5-amino-4,6-dichloropyrimidine 1 with thiophenol or its analog in the presence of base to give 5-amino-4,6-bisphenylthiopyrimidine 6 or an analogue. Additional chemical modification, such as o-methylation, was performed in some instances.
  • the desired cyclization products 2 were prepared according to a Bischler-Napieralski-type reactions using an appropriate acid in PPA/POC1 3 .
  • Analogues of 5-amino-4,6-bisphenylthiopyrimidine 6 can be reacted with a variety of carboxylic acids or derivatives to produce structural diversity among cyclization products 2.
  • the phenylthio group of 2 can be oxidized to produce a number of sulfoxide analogues 8. Nucleophilic substitution of the sulfoxide group generated can add additional chemical diversity, as illustrated by compounds 3.
  • the invention provides a compound of formula:
  • X Cl, R 3 R 4 N, R 3 O, R 3 S, or aryl
  • R 1 , R 2 H, alkyl, substituted alkyl, aryl, substituted aryl or R 1 and R 2 together form a cyclic alkyl;
  • R 3 , R 4 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle.
  • the compound is:
  • Tetracyclic pyrimidine-fused benzodiazepines are benzodiazepines fused with heterocycles such as pyrimidines, indolines and tetrahydroquinolines. See Zheng et al., "Design and Synthesis of a Tetracyclic Pyrimidine-fused Benzodiazepeine Library", In press. The synthetic strategy is based on an electrophilic cyclization reaction involving an iminium intermediate formed by the corresponding aminopyrimidine with a carbonyl compound. The presence of a cyclic indoline or tetrahydroquinoline ring significantly increases the reactiviy of the cyclization compared to open anilino analogs. The chloro group can be replaced with a nucleophile, such as boronic acid, amine, alcohol or thiol, or transition metal catalyzed cross coupling reactions.
  • a nucleophile such as boronic acid, amine, alcohol or thiol, or transition metal catalyzed cross
  • a synthetic strategy starting with pyrimidine 1 in Scheme IV involves saturation of the pyrrole ring of indole moiety (indoline 1) leading to cyclization at the phenyl ring, leading to scaffolds of tetracyclic pyrimidine-fused benzodiazepines 2. Cyclization reactions occur with a wide range of adehydes, including aliphatic and aromatic aldehydes, and aliphatic ketones. The cyclization reactions are expected to follow a similar pathway as the Pictet-Spengler isoquinoline synthesis (Cox et al., Chem Rev 1995, 95, 1797).
  • nucleophiles with heteroatoms such alcohols and thiols are also known to react with 6-chloropurines, exemplified by n-butanol, benzylthiol and thiophenol under basic conditions to give the corresponding rc-butyloxy, benzylsulfanyl or phenylsulfanyl substituted pyrimidobenzediazopines (Lavecchia et al., Tetrahedron Lett 2005, 46, 5851). Introduction of carbon substitutents to replace the chloro further expands the scope of the current library.
  • the invention provides a compound with formula:
  • R 1 , R 2 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle; or R 1 and R 2 together form a cyclic alkyl;
  • R 3 H, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle or substituted heterocycle;
  • R alkyl, substituted alkyl, aryl, substituted aryl.
  • the compound is:
  • Acid derivative refers to a molecule, ion or functional group containing a formyl group (HCO-) or acyl group (RCO-) that is bonded to another atom or functional group, thereby forming one of a range of carbonyl-containing molecules, ions or functional groups such as aldehydes, ketones, acid halides, amides, esters, anhydrides, and thiocarboxylic acids.
  • HCO- formyl group
  • RCO- acyl group
  • Alkyl refers to a cyclic, branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, pentyl, adamantyl. Typically, alkyl groups will comprise 1 to 12 carbon atoms, preferably 1 to 10, and more preferably 1 to 8 carbon atoms. In some embodiments, an alkyl is at least partially unsaturated, such as an alkenyl or alkynyl.
  • Substituted alkyl refers to an alkyl substituted with one or more substituents, e.g., halogen, alkoxy, acyloxy, amino, nitro, hydroxyl, mercapto, carboxy, carboxy derivative, benzyloxy, heterocycle, substituted heterocycle, aryl, substitued aryl, heteroaryl, substituted heteroaryl, and other substituents.
  • substituents e.g., halogen, alkoxy, acyloxy, amino, nitro, hydroxyl, mercapto, carboxy, carboxy derivative, benzyloxy, heterocycle, substituted heterocycle, aryl, substitued aryl, heteroaryl, substituted heteroaryl, and other substituents.
  • Aryl refers to a monovalent unsaturated aromatic carbocyclic group having a single-ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl).
  • Substituted aryl refers to an aryl which is substituted with amino, hydroxyl, lower alkyl, alkoxy, chloro, halo, mercapto, and other substituents.
  • Heteroatom refers to an atom other than carbon. Typically, a heteroatom is oxygen, nitrogen or fluoride.
  • Heterocycle refers to optionally substituted five-membered to eight- membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, partially unsaturated or fully unsaturated (i.e., heteroaryl).
  • Preferred heterocyclic rings include pyridinyl, morpholino, piperidinyl, piperazinyl, 2-amino-imidazoyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyleneimino and heptylmethyleneimino.
  • Substituted heterocycle refers to a heterocycle substituted with, for example, one or more, and preferably one or two, substituents (which are the same or different) which can be halogen, hydroxy, protected hydroxy, cyano, nitro, C 1 to C 12 alkyl, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, C 1 to C 12 acyl, C 1 to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted)amino carboxamide, protected carboxamide, N-(C 1 to C 12 alkyl)carboxamide, protected N-(C 1 to C 12 alkyl)carboxamide, N, N-di(Q to C 12 alkyl)carboxamide, trifluoromethyl, N ⁇ ((((((()
  • Nucleophile refers to an electron-rich molecule, ion, molecular fragment or functional group, typically containing one or more heteroatoms, such as S, O or N, which may be used, for example, in a substitution reaction to displace a leaving group. Typical examples of nucleophiles include amines, alcohols, phenols and thiols.
  • a library of the invention can contain a plurality of the (different) compounds of the invention, hi specific embodiments, a plurality is two or more, three or more, four or more, or five or more of the compounds of the invention, hi another embodiment of the invention, the plurality is ten or more of the compounds of the invention.
  • the plurality is fifteen or more, twenty or more, twenty-five or more, fifty or more of the above-described compounds. If desired, a plurality is 100,000 or more, or even 1,000,000 or more, of the above-described compounds.
  • the compounds of the invention may be used in pharmaceutical compositions as anti-inflammatory, anti-anginal, anti-secretory (gastric acid), anti-muscarinic, antiarrhythmic, anti-depressant, analgesic, anti-psychotic, anxiolytic, anti-convulsant, antineoplastic, anti-mitotic, anti-hypertensive, anti-allergic, anti-asthmatic, antibiotic, antidiabetic, anti-histamine, cadiotonic, and spasmolytic agents, GABA A/benzodiazepine receptor complex related drugs, microtubule inhibitors, endothelin antagonists, muscarinic (M2) antagonists, vasopressin Vl antagonists, vasopressin V2 antagonists, lipoxygenase inhibitors, and treatment for septic shock, irritable bowel syndrome, urinary incontinence, renal failure and neurogenic pain.
  • gastric acid gastric acid
  • anti-muscarinic antiarrhythmic
  • inert, pharmaceutically acceptable carriers are used.
  • the pharmaceutical carrier can be either solid or liquid.
  • Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is generally a finely divided solid which is in a mixture with the finely divided active component.
  • the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the ⁇ shape and size desired.
  • a low- melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.
  • Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient.
  • Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.
  • the pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it.
  • cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration.
  • Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.
  • Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.
  • Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical composition is in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active pyrimidine-fused benzodiazepine compound.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • the compounds of the present invention are generally in a pharmaceutical composition so as to be administered to a subject at dosage levels of from 0.7 to 7000 mg per day, and preferably 1 to 500 mg per day, for a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 0.01 to 100 mg/kg of body weight per day.
  • the specific dosages employed can be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art.
  • Specific binding of library compounds to the enzyme may be detected by any of the numerous enzyme inhibition assays which are well known in the art.
  • Compounds which are bound to the enzyme may be readily separated from compounds which remain free in solution by applying the solution to a Sephadex G-25 gel filtration column. Free enzyme and enzyme-ligand complexes will pass through the column quickly, while free library compounds will be retarded in their progress through the column.
  • the mixture of enzyme-ligand complex and free enzyme can then be treated with a powerful denaturing agent, such as guanidinium hydrochloride or urea, to cause release of the ligand from the enzyme.
  • the solution can then be injected onto an HPLC column (for example, a Vydac C-4 reverse-phase column, eluted with a gradient of water and acetonitrile ranging from 0% acetonitrile to 80% acetonitrile).
  • Diode array detection can provide discrimination of the compounds of the combinatorial library from the enzyme.
  • the compound peaks can then collected and subjected to mass spectrometry for identification.
  • Other assays suitable for testing the compounds of the invention are well known to one of skill in the art.
  • the compounds can be tested against cancer cells or cell lines in vitro for cytotoxicity, e.g, by a method comprising contacting one or more compounds of the invention with a cancer cell, and determining if increased cancer cell death occurs relative to that in the absence of said compounds.
  • the compounds are tested in kinase assays as described in greater detail below.
  • the Z'-LYTETM biochemical assay employs a fluorescence-based, coupled-enzyme format and is based on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage.
  • the peptide substrate is labeled with two fluorophores — one at each end — that make up a FRET pair.
  • the kinase transfers the gamma-phosphate of ATP to a single tyrosine, serine or threonine residue in a synthetic FRET-peptide.
  • a site-specific protease recognizes and cleaves non-phosphorylated FRET-peptides. Phosphorylation of FRET peptides suppresses cleavage by the Development Reagent. Cleavage disrupts FRET between the donor (i.e., coumarin) and acceptor (i.e., fluorescein) fluorophores on the FRET-peptide, whereas uncleaved, phosphorylated FRET-peptides maintain FRET.
  • Emission Ratio Coumarin Emission (445 nrn)/Fluorescein Emission (520 nm)
  • a significant benefit of this ratiometric method for quantitating reaction progress is the elimination of well-to-well variations in FRET-peptide concentration and signal intensities. As a result, the assay yields very high Z '-factor values (>0.7) at a low percent phosphorylation. Both cleaved and uncleaved FRET-peptides contribute to the fluorescence signals and therefore to the Emission Ratio. The extent of phosphorylation of the FRET-peptide can be calculated from the Emission Ratio.
  • the Emission Ratio will remain low if the FRET-peptide is phosphorylated (i.e., no kinase inhibition) and will be high if the FRET-peptide is non-phosphorylated (i.e., kinase inhibition).
  • All Test Inhibitor Compounds will be initially diluted to a IOOX concentration in 100% DMSO. The IOOX concentration will then diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA). The Test Inhibitor Compounds will be in 1% DMSO final in the well.
  • ATP Solution All ATP Solutions will be diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA).
  • Kinase Buffer 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • Development Reagent Solution The Development Reagent will be diluted in
  • Assay plate will be shaken on a plate shaker for 30 seconds.
  • Assay plate will be incubated for 60 minutes at room temperature.
  • Assay plate will be shaken on a plate shaker for 30 seconds.
  • Assay plate will be read on fluorescence plate reader and the data is analyzed.
  • a ASSAY CONTROLS The following controls will be made for each indiyidual kinase and will be located on the same plate as the kinase: [00374] 0% Phosphorylation Control (100% Inhibition Control). The maximum
  • Emission Ratio will be established by the 0% Phosphorylation Control (100% Inhibition Control), which will contain no ATP and therefore will exhibit no kinase activity. This control will yield 100% cleaved peptide in the Development Reaction. [00375] 100% Phosphorylation Control.
  • the 100% Phosphorylation Control which will consist of a synthetically phosphorylated peptide of the same sequence as the peptide substrate, will be designed to allow for the calculation of percent phosphorylation. This control will yield a very low percentage of cleaved peptide in the Development Reaction.
  • the 0% Phosphorylation and 100% Phosphorylation Controls will allow one to calculate the percent Phosphorylation achieved in a specific reaction well. Control wells will not include any kinase inhibitors.
  • 0% Inhibition Control The minimum Emission Ratio in a screen will be established by the 0% Inhibition Control, which will contain active kinase. This control will be designed to produce a 10-50% phosphorylated peptide in the Kinase Reaction and to yield 60-80% cleaved peptide in the Development Reaction.
  • Known Inhibitor A known inhibitor control standard curve, 10 point titration, will be run for each individual kinase on the same plate as the kinase to ensure the kinase will be inhibited within an expected IC50 range previously determined as well as R2 and
  • Development Reaction Interference will be established by comparing the Test Compound Control wells that do not contain ATP versus the 0% Phosphorylation Control (which will not contain the Test Compound).
  • Test Compound Fluorescence Interference The Test Compound Fluorescence
  • Control Co% Average Coumarin emission signal of the 0% Phos.
  • Control Fioo% Average Fluorescein emission signal of the 100% Phos.
  • Control Fo % Average Fluorescein emission signal of the 0% Phos.
  • SelectScreenTM Kinase Profiling Service uses XLfit from IDBS.
  • the dose response curve will be curve fit to model number 205 (sigmoidal dose-response model). If the bottom of the curve does not fit between -20% & 20% inhibition, it will be set to 0% inhibition. If the top of the curve does not fit between 70% and 130% inhibition, it will be set to 100% inhibition.
  • the 2X ABLl / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.4 - 2.8 ng ABLl and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • Reaction will consist of 0.8 - 5.2 ng ABLl E255K and 2 ⁇ M Tyr 02 Peptide in 50 mM
  • Reaction will consist of 0.8 - 7.9 ng ABLl G250E and 2 ⁇ M Tyr 02 Peptide in 50 mM
  • Reaction will consist of 0.7 - 5.2 ng ABLl Y253F and 2 ⁇ M Tyr 02 Peptide in 50 mM
  • Reaction will consist of 0.4 - 5.3 ng ABL2 (Arg) and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:64 dilution of Development Reagent A will be added.
  • the 2X ACVRlB (ALK4) / Ser/Thr 16 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnC12, 1 mM EGTA, 2 mM DTT, 0.02%
  • the final 10 ⁇ L Kinase Reaction will consist of 10.0 - 62.2 ng ACVRlB (ALK4) and
  • ADRBK2 (GRK3)
  • kinase Reaction will consist of 9.9 - 89.0 ng ADRB K2 (GRK3) and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour
  • AKTl (PKB alpha) [00404] The 2X AKTl (PKB alpha) / Ser/Thr 06 Peptide Mixture will be prepared in
  • Kinase Reaction will consist of 0.5 - 8.6 ng AKTl (PKB alpha) and 2 ⁇ M Ser/Thr 06 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour
  • AKT2 (PKB beta)
  • the 2X AKT2 (PKB beta) / Ser/Thr 06 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • Reaction will consist of 1.0 - 40.0 ng AKT2 (PKB beta) and 2 ⁇ M Ser/Thr 06 Peptide in 50 mM HEPES pH 7.5, 0.01% BRLF-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase
  • AKT3 (PKB gamma)
  • Kinase Reaction will consist of 0.4 - 8.3 ng AKT3 (PKB gamma) and 2 ⁇ M Ser/Thr 06
  • the final 10 ⁇ L Kinase Reaction will consist of 20.3 - 243.5 ng ALK and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • Kinase Reaction will consist of 11.1 - 155.4 ng AURKB (Aurora B) and 2 ⁇ M Ser/Thr 01
  • BLK [00414] The 2X BLK / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH
  • the 2X CAMKlD (CaMKI delta) / Ser/Thr 10 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 20 ⁇ g/ml Calmodulin, 0.02% NaN3.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.1 - 40.0 ng CAMKlD (CaMKI delta) and 2 ⁇ M Ser/Thr 10 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, 10 ⁇ g/ml Calmodulin, 0.01% NaN3.
  • 5 ⁇ L of a 1:2048 dilution of Development Reagent A will be added.
  • CAMK2A (CaMKII alpha)
  • the 2X CAMK2A (CaMKII alpha) / Ser/Thr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM CaC12, 20 ⁇ g/ml Calmodulin, 0.02% NaN3.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.3 - 4.8 ng CAMK2A (CaMKII alpha) and 2 ⁇ M Ser/Thr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, 10 ⁇ g/ml Calmodulin, 0.01% NaN3.
  • 5 ⁇ L of a 1:1024 dilution of Development Reagent A will be added.
  • CAMK2B (CaMKII beta)
  • the 2X CAMK2B (CaMKII beta) / Ser/Thr 10 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 20 ⁇ g/ml
  • CAMK2B (CaMKII beta) and 2 ⁇ M Ser/Thr 10 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • BRIJ-35 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, 10 ⁇ g/ml Calmodulin, 0.01% NaN3.
  • Reagent A will be added.
  • CAMK2D (CaMKII delta)
  • the 2X CAMK2D (CaMKII delta) / Ser/Thr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 20 ⁇ g/ml
  • CAMK2D (CaMKII delta) and 2 ⁇ M Ser/Thr 04 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • BRIJ-35 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, 10 ⁇ g/ml Calmodulin, 0.01% NaN3.
  • Reagent A will be added.
  • CAMK4 (CaMKIV)
  • the 2X CDKl/cyclin B / Ser/Thr 12 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • Reaction will consist of 0.3 - 3.5 ng CDKl/cyclin B and 2 ⁇ M Ser/Thr 12 Peptide in 50 mM
  • the 2X CDK2/cyclin A / Ser/Thr 12 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • the 2X CHEKl (CHKl) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, ImM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 4.0 - 115.2 ng CHEKl (CHKl) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • the 2X CHEK2 (CHK2) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 6.0 - 400.0 ng CHEK2 (CHK2) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.0 - 26.0 ng CSK and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X CSNKlAl (CKl alpha 1) / Ser/Thr 11 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA, 2 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 16.7 - 107.0 ng CSNKlAl (CKl alpha
  • the 2X CSNKlD (CKl delta) / Ser/Thr 11 Peptide Mixture will be prepared in 50 mM Tris pH 8.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA, 0.02% NaN3. The final 10 ⁇ L Kinase Reaction will consist of 17.2 - 138.2 ng CSNKlD (CKl delta) and 2 ⁇ M
  • the 2X CSNKlE (CKl epsilon) / Ser/Thr 11 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L
  • CSNKlGl (CKl gamma 1)
  • the 2X CSNKlGl (CKl gamma 1) / Ser/Thr 05 Peptide Mixture will be prepared in 50 niM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final
  • Reagent B will be added.
  • the 2X CSNK1G2 (CKl gamma 2) / Ser/Thr 05 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final
  • Reagent B will be added.
  • the 2X CSNK1G3 (CKl gamma 3) / Ser/Thr 05 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final
  • Reagent B will be added.
  • the 2X CSNK2A1 (CK2 alpha 1) / Ser/Thr 11 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final
  • the 2X CSNK2A2 (CK2 alpha 2) / Ser/Thr 11 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final
  • the 2X DAPK3 (ZIPK) / Ser/Thr 13 Peptide Mixture will be prepared in 50 niM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 11.6 - 80.0 ng DAPK3 (ZIPK) and 2 ⁇ M Ser/Thr 13 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:512 dilution of Development Reagent A will be added.
  • the 2X EGFR L858R (ErbB 1 L858R) / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.6 - 4.5 ng EGFR L858R (ErbBl L858R) and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32 dilution of Development Reagent B will be added.
  • EGFR L861Q (ErbB 1 L861Q)
  • the 2X EGFR L861Q (ErbB 1 L861Q) / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM MnC12, 1 mM
  • the 2X EPHAl / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 5.5 - 60.7 ng EPHAl and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHA2 / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 1.2 - 26.2 ng EPHA2 and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHA3 / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.3 - 145.5 ng EPHA3 and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHA4 / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 5.8 - 23.0 ng EPHA4 and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHA5 / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 1.5 - 38.1 ng EPHA5 and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:128 dilution of Development Reagent B will be added.
  • the 2X EPHA8 / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 3.2 - 49.1 ng EPHA8 and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHB 1 / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.4 - 63.1 ng EPHBl and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHB2 / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.7 - 18.0 ng EPHB2 and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHB3 / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.0 - 43.8 ng EPHB3 and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X EPHB4 / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 1.3 - 18.0 ng EPHB4 and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • ERBB2 (HER2)
  • the final 10 ⁇ L Kinase Reaction will consist of 4.1 - 34.1 ng ERBB2 (HER2) and 2 ⁇ M Tyr
  • the final 10 ⁇ L Kinase Reaction will consist of 2.0 - 23.0 ng ERBB4 (HER4) and 2 ⁇ M Tyr
  • the final 10 ⁇ L Kinase Reaction will consist of 1.6 - 21.7 ng FER and 2 ⁇ M Tyr 05 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • Reaction will consist of 0.7 - 5.2 ng FES (FPS) and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:128 dilution of Development Reagent B will be added.
  • the 2X FGFRl / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT. The final
  • FGFR2 [00506] The 2X FGFR2 / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT. The final 10 ⁇ L Kinase Reaction will consist of 0.3 - 2.9 ng FGFR2 and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32 dilution of Development Reagent B will be added. [00508] FGFR3
  • the 2X FGFR3 / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT.
  • the final 10 ⁇ L Kinase Reaction will consist of 1.4 - 20.0 ng FGFR3 and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM DTT.
  • 5 ⁇ L of a 1:32 dilution of Development Reagent B will be added.
  • the 2X FGFR4 / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.4 - 105.0 ng FGFR4 and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM DTT.
  • 5 ⁇ L of a 1:32 dilution of Development Reagent B will be added.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.6 - 76.0 ng FLT3 and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • Reaction will consist of 0.1 - 1.3 ng FLT3 D835Y and 2 ⁇ M Tyr 02 Peptide in 50 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 1.9 - 16.0 ng FLT4 (VEGFR3) and 2 ⁇ M Tyr
  • Reaction will consist of 1.1 - 51.9 ng FRK (PTK5) and 2 ⁇ M Tyr 01 Peptide in 50 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 5.0 - 34.0 ng FYN and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • Reaction will consist of 1.3 - 9.6 ng GRK4 and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BR ⁇ -35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:8 dilution of Development Reagent B will be added.
  • the final 10 ⁇ L Kinase Reaction will consist of 12.1 - 97.5 ng GRK5 and 2 ⁇ M Ser/Thr 16
  • Reaction will consist of 9.1 - 82.9 ng GRK6 and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:8 dilution of Development Reagent B will be added.
  • Reaction will consist of 3.8 - 28.5 ng GRK7 and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:8 dilution of Development Reagent B will be added.
  • GSK3A (GSK3 alpha)
  • the 2X GSK3A (GSK3 alpha) / Ser/Thr 09 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L
  • GSK3B (GSK3 beta)
  • the 2X IGFlR / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 3.8 - 98.8 ng IGFlR and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:128 dilution of Development Reagent B will be added.
  • KDR (VEGFR2)
  • the final 10 ⁇ L Kinase Reaction will consist of 4.8 - 127.0 ng KIT T670I and 2 ⁇ M Tyr 06
  • the final 10 ⁇ L Kinase Reaction will consist of 2.0 - 26.5 ng LCK and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X LYN A / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 1.1 - 12.0 ng LYN A and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X LYN B / Tyr 02 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.9 - 18.5 ng LYN B and 2 ⁇ M Tyr 02 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • MAP3K9 (MLKl) [00569] The 2X MAP3K9 (MLKl) / Ser/Thr 07 Peptide Mixture will be prepared in
  • MAP4K2 / Ser/Thr 07 Peptide Mixture
  • the 2X MAP4K2 (GCK) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.4 - 8.4 ng MAP4K2 (GCK) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • the 2X MAP4K4 (HGK) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.5 - 5.0 ng MAP4K4 (HGK) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • the 2X MAP4K5 (KHS 1) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.3 - 4.0 ng MAP4K5 (KHSl) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • MAPKl ERK2
  • the 2X MAPKl (ERK2) / Ser/Thr 03 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.1 - 31.4 ng MAPKl (ERK2) and 2 ⁇ M Ser/Thr 03 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:1024 dilution of Development Reagent A will be added.
  • MAPK12 (p38 gamma)
  • the 2X MAPK12 (p38 gamma) / Ser/Thr 03 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L
  • Kinase Reaction will consist of 0.5 - 4.8 ng MAPK12 (p38 gamma) and 2 ⁇ M Ser/Thr 03
  • the 2X MAPK3 (ERKl) / Ser/Thr 03 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • Reaction will consist of 2.5 - 31.5 ng MAPK3 (ERKl) and 2 ⁇ M Ser/Thr 03 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase
  • Reaction will consist of 0.1 - 0.3 ng MAPKAPK2 and 2 ⁇ M Ser/Thr 04 Peptide in 50 mM
  • Reaction will consist of 0.8 - 15.8 ng MAPKAPK3 and 2 ⁇ M Ser/Thr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 niM MgC12, 1 mM EGTA. After the 1 hour Kinase
  • the 2X MAPKAPK5 (PRAK) / Ser/Thr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L
  • Reaction will consist of 2.9 - 76.8 ng MATK (HYL) and 2 ⁇ M Tyr 01 Peptide in 50 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 0.7 - 7.8 ng MERTK (cMER) and 2 ⁇ M Tyr
  • Reaction will consist of 1.3 - 10.0 ng MET (cMet) and 2 ⁇ M Tyr 06 Peptide in 50 mM
  • Reaction will consist of 3.0 - 30.0 ng MET M1250T and 2 ⁇ M Tyr 06 Peptide in 50 mM
  • Reaction will consist of 1.2 - 35.0 ng MINKl and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM
  • Reaction will consist of 0.1 - 1.2 ng MSTlR (RON) and 2 ⁇ M Tyr 06 Peptide in 50 mM
  • Reaction will consist of 10.5 - 89.8 ng MST4 and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added
  • the 2X MUSK / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT. The final
  • 10 ⁇ L Kinase Reaction will consist of 16.4 - 89.5 ng MUSK and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM
  • Reagent B will be added.
  • NEKl [00611] The 2X NEKl / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM
  • Reaction will consist of 1.9 - 69.1 ng NEKl and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • Reaction will consist of 0.4 - 4.0 ng NEK2 and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • Reaction will consist of 4.8 - 77.4 ng NTRKl (TRKA) and 2 ⁇ M Tyr 01 Peptide in 50 mM
  • NTRK2 (TRKB)
  • the final 10 ⁇ L Kinase Reaction will consist of 0.2 - 2.0 ng NTRK2 (TRKB) and 2 ⁇ M Tyr
  • NTRK3 (TRKC)
  • Reaction will consist of 3.3 - 110.6 ng NTRK3 (TRKC) and 2 ⁇ M Tyr 01 Peptide in 50 mM
  • Reaction will consist of 3.8 - 68.0 ng PAK3 and 2 ⁇ M Ser/Thr 14 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:256 dilution of Development Reagent A will be added.
  • Reaction will consist of 0.1 - 0.5 ng PAK4 and 2 ⁇ M Ser/Thr 14 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:256 dilution of Development Reagent A will be added.
  • Reaction will consist of 2.0 - 12.6 ng PAK6 and 2 ⁇ M Ser/Thr 14 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:256 dilution of Development Reagent A will be added.
  • Reaction will consist of 10.5 - 59.8 ng PASK and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • the 2X PDGFRA (PDGFR alpha) / Tyr 04 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM MnC12, 1 mM EGTA, 2 mM DTT.
  • the final 10 ⁇ L Kinase Reaction will consist of 4.0 - 132.8 ng PDGFRA (PDGFR alpha) and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 2 mM MnC12, 1 mM EGTA, 1 mM DTT.
  • 5 ⁇ L of a 1:32 dilution of Development Reagent B will be added.
  • the final 10 ⁇ L Kinase Reaction will consist of 4.4 - 39.6 ng PDGFRA D842V and 2 ⁇ M Tyr
  • the final 10 ⁇ L Kinase Reaction will consist of 14.6 - 58.4 ng PDGFRA T674I and 2 ⁇ M Tyr
  • PDGFRB (PDGFR beta)
  • the final 10 ⁇ L Kinase Reaction will consist of 4.8 - 33.0 ng PDGFRB (PDGFR beta) and 2 ⁇ M Tyr 04 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 2 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 6.3 - 117.8 ng PHKGl and 2 ⁇ M
  • Reagent A will be added.
  • the 2X PIMl / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.8 - 39.4 ng PIMl and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X PIM2 / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.5 - 25.0 ng PIM2 and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01%
  • the 2X PKNl (PRKl) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM Tris pH 8.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA, 0.02% NaN3.
  • the final 10 ⁇ L Kinase Reaction will consist of 2.9 - 29.8 ng PKNl (PRKl) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM Tris / HEPES pH 8.0, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA, 0.01% NaN3.
  • Reagent A will be added.
  • Reaction will consist of 2.8 - 25.3 ng PLKl and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1 :8 dilution of Development Reagent B will be added.
  • Reaction will consist of 13.0 - 186.2 ng PLK2 and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM
  • Reaction will consist of 0.8 - 4.5 ng PLK3 and 2 ⁇ M Ser/Thr 16 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1:8 dilution of Development Reagent B will be added.
  • the 2X PRKACA (PKA) / Ser/Thr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.0 - 0.1 ng PRKACA (PKA) and 2 ⁇ M Ser/Thr 01 Peptide in 50 mM HEPES pH 7.5, 0.01% BRD-35, 10 mM MgC12, 1 niM EGTA.
  • PKA 2X PRKACA
  • Ser/Thr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.0 - 0.1 ng PRKACA (PKA) and 2 ⁇ M Ser/Thr 01 Peptide in 50 mM
  • PRKCA PLC alpha
  • the final 10 ⁇ L Kinase Reaction will consist of 0.0 - 0.3 ng PRKCA (PKC alpha) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM
  • PRKCB 1 PLC beta I
  • the 2X PRKCB 1 (PKC beta I) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 2X Novel Lipid
  • PLC beta I Peptide beta I
  • 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • PRKCB2 (PKC beta II)
  • the 2X PRKCB2 (PKC beta II) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 2X Novel Lipid
  • PLC beta II Peptide beta II
  • 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • PRKCD PLC delta
  • the final 10 ⁇ L Kinase Reaction will consist of 0.1 - 1.3 ng PRKCD (PKC delta) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM
  • PRKCE PLC epsilon
  • the 2X PRKCE (PKC epsilon) / Ser/Thr 07 Peptide Mixture will be prepared in 50 niM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 4 mM CaC12, 2X Novel Lipid
  • PLC epsilon Peptide epsilon
  • 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • PRKCG PKC gamma
  • the 2X PRKCG (PKC gamma) / Ser/Thr 07 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 4 mM CaC12, 2X Novel Lipid
  • PLC gamma Peptide gamma
  • 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • 5 ⁇ L of a 1:32768 dilution of Development Reagent A will be added.
  • PRKCH (PKC eta)
  • the final 10 ⁇ L Kinase Reaction will consist of 0.1 - 1.1 ng PRKCH (PKC eta) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • PKC eta PRKCH
  • Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • the final 10 ⁇ L Kinase Reaction will consist of 0.8 - 5.0 ng PRKCI (PKC iota) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • PRKCN (PKD3)
  • the 2X PRKCN (PKD3) / Ser/Thr 10 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • Reaction will consist of 0.3 - 5.8 ng PRKCN (PKD3) and 2 ⁇ M Ser/Thr 10 Peptide in 50 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 0.0 - 0.4 ng PRKCQ (PKC theta) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM
  • PRKCZ PLC zeta
  • the final 10 ⁇ L Kinase Reaction will consist of 0.9 - 8.0 ng PRKCZ (PKC zeta) and 2 ⁇ M Ser/Thr 07 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 500 ⁇ M EGTA, 2 mM CaC12, IX Novel Lipid Mix, 0.01% NaN3.
  • Kinase Reaction will consist of 0.1 - 1.7 ng PRKDl (PKC mu) and 2 ⁇ M Ser/Thr 10 Peptide in 50 mM HEPES pH 7.5, 0.01% BRJJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour
  • the 2X PRKD2 (PKD2) / Ser/Thr 10 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. The final 10 ⁇ L Kinase
  • Reaction will consist of 0.2 - 2.4 ng PRKD2 (PKD2) and 2 ⁇ M Ser/Thr 10 Peptide in 50 mM
  • PRKGl [00681] The 2X PRKGl / Ser/Thr 14 Peptide Mixture will be prepared in 50 rnM
  • the final 10 ⁇ L Kinase Reaction will consist of 0.1 - 0.8 ng PRKGl and 2 ⁇ M Ser/Thr 14 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA, 10 ⁇ M cGMP.
  • the 2X PRKG2 (PKG2) / Ser/Thr 14 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA, 20 ⁇ M cGMP. The final
  • 10 ⁇ L Kinase Reaction will consist of 0.1 - 2.0 ng PRKG2 (PKG2) and 2 ⁇ M Ser/Thr 14
  • Reagent A will be added.
  • Reaction will consist of 0.3 - 2.8 ng PRKX and 2 ⁇ M Ser/Thr 14 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 ⁇ L of a 1 :256 dilution of Development Reagent A will be added.
  • Reaction will consist of 2.7 - 40.1 ng PTK2 (FAK) and 2 ⁇ M Tyr 01 Peptide in 50 mM
  • the final 10 ⁇ L Kinase Reaction will consist of 17.5 - 400.0 ng PTK6 (Brk) and 2 ⁇ M Tyr 01
  • RET [00691] The 2X RET / Tyr 02 Peptide Mixture will be prepared in 50 rnM HEPES pH
  • the 2X ROS 1 / Tyr 01 Peptide Mixture will be prepared in 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgC12, 1 mM EGTA.
  • the final 10 ⁇ L Kinase Reaction will consist of 3.6 - 23.9 ng ROSl and 2 ⁇ M Tyr 01 Peptide in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgC12, 1 mM EGTA.
  • 5 ⁇ L of a 1:128 dilution of Development Reagent B will be added.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des composés dérivés de benzodiazépine fusionnés pyrimidine et des composés ptéridines fusionnées indole. L'invention concerne également des banques contenant au moins deux de ces composés, ainsi que des procédés de fabrication desdits composés. L'invention concerne encore des procédés de criblage de composés dérivés de benzodiazépine fusionnés pyrimidine et de composés ptéridines fusionnées indole bioactifs.
EP06748243A 2005-02-18 2006-02-21 Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole Withdrawn EP1848506A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65460605P 2005-02-18 2005-02-18
PCT/US2006/006303 WO2006089298A2 (fr) 2005-02-18 2006-02-21 Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole

Publications (1)

Publication Number Publication Date
EP1848506A2 true EP1848506A2 (fr) 2007-10-31

Family

ID=36917171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06748243A Withdrawn EP1848506A2 (fr) 2005-02-18 2006-02-21 Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole

Country Status (3)

Country Link
EP (1) EP1848506A2 (fr)
CN (1) CN101257948A (fr)
WO (1) WO2006089298A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102203B1 (fr) * 2007-04-11 2016-02-17 Merck Sharp & Dohme B.V. Procédé de préparation de benzazépine énantiomorphiquement pure
JP5303561B2 (ja) * 2008-08-12 2013-10-02 日本曹達株式会社 含窒素ヘテロ環誘導体および農園芸用殺菌剤
JP5442021B2 (ja) 2009-09-28 2014-03-12 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤
ME03376B (fr) 2010-05-20 2020-01-20 Array Biopharma Inc Composés macrocycliques comme inhibiteurs de la kinase trk
CN102690278B (zh) * 2011-03-21 2015-07-15 长春吉大天元化学技术股份有限公司 新颖嘧啶并环化合物作为细胞因子抑制剂
CN102807574B (zh) * 2011-05-30 2015-09-02 长春吉大天元化学技术股份有限公司 新型吡啶并硫氮七元环衍生物作为抗肿瘤药物、及其制备方法和应用
CN103509024B (zh) * 2012-06-28 2015-10-28 上海医药工业研究院 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
MX387025B (es) * 2016-03-04 2025-03-19 Anhui New Star Pharmaceutical Dev Co Ltd Compuestos de anillo de siete miembros de pirimidina
WO2017165300A1 (fr) * 2016-03-21 2017-09-28 Regents Of The University Of Minnesota Composés indole et indazole et leurs utilisations thérapeutiques
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (fr) 2017-01-18 2018-07-26 Andrews Steven W Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3728268A4 (fr) * 2017-12-22 2021-07-28 Dana-Farber Cancer Institute, Inc. Inhibiteurs de nek et procédés d'utilisation
EP3740490A1 (fr) 2018-01-18 2020-11-25 Array Biopharma, Inc. Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
KR102498531B1 (ko) * 2020-06-29 2023-02-13 한국과학기술연구원 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009384A2 (fr) * 2003-07-21 2005-02-03 Imclone Systems Incorporated Inhibiteurs de la tyrosine kinase egfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006089298A2 *

Also Published As

Publication number Publication date
CN101257948A (zh) 2008-09-03
WO2006089298A2 (fr) 2006-08-24
WO2006089298A3 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2006089298A2 (fr) Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole
Rewcastle et al. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
Demeunynck et al. Survey of recent literature related to the biologically active 4 (3H)-quinazolinones containing fused heterocycles
EP1556384B1 (fr) Composes pyrimido presentant une activite antiproliferative
Traxler et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines
Kim et al. Synthesis and biological evaluations of pyrazolo [3, 4-d] pyrimidines as cyclin-dependent kinase 2 inhibitors
Ismail et al. Medicinal attributes of pyrazolo [1, 5-a] pyrimidine based scaffold derivatives targeting kinases as anticancer agents
EP1180105B1 (fr) Derives d'aza-oxindole substitues
US6395733B1 (en) Heterocyclic ring-fused pyrimidine derivatives
TW201906848A (zh) 化學化合物
Capps et al. 2-(Aminoalkyl)-5-nitropyrazolo [3, 4, 5-kl] acridines, a new class of anticancer agents
EP0400974A2 (fr) Antagonistes d'angiotensine II du type imidazo condensé à un hétérocycle à 6 chaînons substitués
CZ164196A3 (en) Pyrimidine derivatives with condensed heterocyclic ring and pharmaceutical compositions based thereon
WO2009077956A2 (fr) INHIBITEURS HÉTÉROCYCLIQUES D'UNE CASCADE DE SIGNAUX Hh, COMPOSITIONS MÉDICINALES À BASE DE CES INHIBITEURS ET MÉTHODES DE TRAITEMENT DE MALADIES PROVOQUÉES PAR L'ACTIVITÉ ABERRANTE DU SYSTÈME DE SIGNALISATION Hh
EP1080092A2 (fr) Pyrimidines bicycliques et 3,4-dihydropyrimidines bicycliques, inhibiteurs de proliferation cellulaire
AU2003294830A1 (en) Pyridino `2, 3-D! pyrimidine derivatives as selective KDR and FGFR inhibitors
Martin et al. Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido [5′, 4′: 5, 6] pyrimido [1, 2-a] benzimidazol-5 (6 H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity
KR20080072886A (ko) ＥＰＨＢ 및 ＶＥＧＦＲ2 키나제 억제제로서의 3-(치환아미노)-피라졸로[3,4-ｄ]피리미딘
CA2585660A1 (fr) Inhibiteurs de kinases de type pyrazolopyrimidines 1,4-substituees
US6624171B1 (en) Substituted aza-oxindole derivatives
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
Dickens et al. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2
KR101897631B1 (ko) 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 골격의 유레아 화합물
Gazizov et al. Access to azolopyrimidine-6, 7-diamines as a valuable “building-blocks” to develop new fused heteroaromatic systems
Alberti et al. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido [1′, 2′: 1, 5] pyrazolo [3, 4-d] pyrimidines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070827

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090901